571 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B Downtrend
Article Searches
6 Stocks to Prepare for a Global Economic Slowdown http://www.zacks.com/stock/news/348943/6-stocks-to-prepare-for-a-global-economic-slowdown?cid=CS-ZC-FT-348943 Jan 23, 2019 - A slowdown in Europe and the ongoing trade conflicts have been cited as the major reasons for the IMF's projection cuts.
3 Upcoming Readouts for Gilead Sciences You Don't Want to Miss https://www.fool.com/investing/2019/01/23/3-upcoming-readouts-for-gilead-sciences-you-dont-w.aspx?source=iedfolrf0000001 Jan 23, 2019 - Results from a few clinical trials reading out in 2019 could make it a year to remember.
Company News For Jan 22, 2019 http://www.zacks.com/stock/news/348839/company-news-for-jan-22-2019?cid=CS-ZC--348839 Jan 22, 2019 - Companies In The News Are: TIF,LLY,KSU,JBHT
Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY http://www.zacks.com/stock/news/348355/pharma-stock-roundup-regulatory-updates-in-focus-at-pfe-bmy-rhhby-sny?cid=CS-ZC-FT-348355 Jan 18, 2019 - Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.
Here is Why Growth Investors Should Buy Lilly (LLY) Now http://www.zacks.com/stock/news/348332/here-is-why-growth-investors-should-buy-lilly-lly-now?cid=CS-ZC-FT-348332 Jan 18, 2019 - Lilly (LLY) possesses solid growth attributes, which could help it handily outperform the market.
Intrexon Signs Licensing Agreement with Next Green Wave http://www.zacks.com/stock/news/347858/intrexon-signs-licensing-agreement-with-next-green-wave?cid=CS-ZC-FT-347858 Jan 16, 2019 - Intrexon (XON) partners with Next Green Wave Holdings to utilize Intrexon's Botticelli next-generation plant propagation platform.
Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer http://www.zacks.com/stock/news/347471/bristol-myers-drug-combination-gets-eu-nod-for-renal-cancer?cid=CS-ZC-FT-347471 Jan 15, 2019 - Bristol-Myers (BMY) gets EU approval for the immuno-oncology combination of Opdivo and low-dose Yervoy for the first-line treatment of patients with intermediate- and poor-risk advanced RCC.
Here's Why Loxo Oncology Soared 66.4% in 2018, and Another 66% Since https://www.fool.com/investing/2019/01/13/heres-why-loxo-oncology-soared-664-in-2018-and-ano.aspx?source=iedfolrf0000001 Jan 13, 2019 - The biopharma delivered the goods with its drug pipeline, scored marketing approval for its lead drug candidate, and agreed to be acquired for $8 billion.
Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet http://www.zacks.com/stock/news/347005/pharma-stock-roundup-lilly-to-buy-loxo-for-%248b-ma-in-focus-at-jp-morgan-meet?cid=CS-ZC-FT-347005 Jan 11, 2019 - Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.
4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019 http://www.zacks.com/stock/news/346884/4-pharma-biotech-pipeline-areas-to-keep-an-eye-on-in-2019?cid=CS-ZC-FT-346884 Jan 11, 2019 - Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.

Pages: 1...4567891011121314...58

<<<Page 9>